Filing Flows › Jazz Pharmaceuticals (JAZZ) › Capital expenditures
Jazz Pharmaceuticals (JAZZ) capital expenditures by quarter
Jazz Pharmaceuticals' capital expenditures were $16.2M in Q3 2026 (third quarter 2026), -10% from Q2 2026. Over the last 7 quarters it ranged from $12.9M (Q2 2025) to $19.7M (Q1 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $16.2M | -10% | +7% |
| Q2 2026 | $18.1M | -8% | +40% |
| Q1 2026 | $19.7M | +18% | +42% |
| Q4 2025 | $16.8M | +10% | — |
| Q3 2025 | $15.2M | +18% | — |
| Q2 2025 | $12.9M | -7% | — |
| Q1 2025 | $13.9M | — | — |
Q3 2026 at a glance
Jazz Pharmaceuticals, Q3 2026: revenue $1.2B (+10% year over year), operating margin -33.3%, net loss $483M, operating cash flow $506M. The chart follows the revenue to costs, profit and cash.
Questions
What is Jazz Pharmaceuticals' capital expenditures?
Jazz Pharmaceuticals' capital expenditures were $16.2M in Q3 2026 (third quarter 2026), -10% from Q2 2026.
How has Jazz Pharmaceuticals' capital expenditures changed?
Over the last 7 quarters it ranged from $12.9M (Q2 2025) to $19.7M (Q1 2026).